Evidence map›Paper›PMID 38067805›Full record

ReviewSensors (Basel, Switzerland)2023

Emerging Microfluidic Tools for Simultaneous Exosomes and Cargo Biosensing in Liquid Biopsy: New Integrated Miniaturized FFF-Assisted Approach for Colon Cancer Diagnosis.

Valentina Marassi, Stefano Giordani, Anna Placci, Angela Punzo, Cristiana Caliceti, Andrea Zattoni, Pierluigi Reschiglian, Barbara Roda, Aldo Roda

Open access · goldAbstract readReview
In one paragraph

Review in Sensors (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Valentina MarassiDepartment of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-8742-3708
Stefano GiordaniDepartment of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.
Anna PlacciDepartment of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.
Angela PunzoNational Institute of Biostructure and Biosystems (INBB), 00136 Rome, Italy.ORCID 0000-0003-3026-6830
Cristiana CalicetiNational Institute of Biostructure and Biosystems (INBB), 00136 Rome, Italy.ORCID 0000-0002-6740-5331
Andrea ZattoniDepartment of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-6971-5360
Pierluigi ReschiglianDepartment of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.
Barbara RodaDepartment of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.ORCID 0000-0003-1060-2921
Aldo RodaDepartment of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-7649-4797
Istituto Nazionale Biostrutture e Biosistemi · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The early-stage diagnosis of cancer is a crucial clinical need. The inadequacies of surgery tissue biopsy have prompted a transition to a less invasive profiling of molecular biomarkers from biofluids, known as liquid biopsy. Exosomes are phospholipid bilayer vesicles present in many biofluids with a biologically active cargo, being responsible for cell-to-cell communication in biological systems. An increase in their excretion and changes in their cargo are potential diagnostic biomarkers for an array of diseases, including cancer, and they constitute a promising analyte for liquid biopsy. The number of exosomes released, the morphological properties, the membrane composition, and their content are highly related to the physiological and pathological states. The main analytical challenge to establishing liquid biopsy in clinical practice is the development of biosensors able to detect intact exosomes concentration and simultaneously analyze specific membrane biomarkers and those contained in their cargo. Before analysis, exosomes also need to be isolated from biological fluids. Microfluidic systems can address several issues present in conventional methods (i.e., ultracentrifugation, size-exclusion chromatography, ultrafiltration, and immunoaffinity capture), which are time-consuming and require a relatively high amount of sample; in addition, they can be easily integrated with biosensing systems. A critical review of emerging microfluidic-based devices for integrated biosensing approaches and following the major analytical need for accurate diagnostics is presented here. The design of a new miniaturized biosensing system is also reported. A device based on hollow-fiber flow field-flow fractionation followed by luminescence-based immunoassay is applied to isolate intact exosomes and characterize their cargo as a proof of concept for colon cancer diagnosis.

Indexed as

Colonic NeoplasmsExosomesBiomarkersCell CommunicationHumansLiquid BiopsyMicrofluidicsBiomarkerscolon cancerexosomeshollow-fiber field-flow fractionationliquid biopsyluminescencemicrofluidicminiaturizationreagent less biosensors

Identifiers

PMID38067805
PMCPMC10708636
OpenAlexW4389051163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.